Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

BACKGROUND: Azithromycin, an antibiotic with potential antiviral and anti-inflammatory properties, has been used to treat COVID-19, but evidence from community randomised trials is lacking. We aimed to assess the effectiveness of azithromycin to treat suspected COVID-19 among people in the community...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972318/
https://www.ncbi.nlm.nih.gov/pubmed/33676597
http://dx.doi.org/10.1016/S0140-6736(21)00461-X

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972318/
https://www.ncbi.nlm.nih.gov/pubmed/33676597
http://dx.doi.org/10.1016/S0140-6736(21)00461-X

Ejemplares similares